Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
About this item
Full title
Author / Creator
Publisher
Boston, MA: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Boston, MA: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
The t(9;22) translocation that forms the Philadelphia chromosome of chronic myelogenous leukemia (CML) also forms a fusion gene,
BCR-ABL
. The new gene encodes an abnormal tyrosine kinase, which causes the leukemia. Imatinib mesylate inhibits the function of the BCR-ABL protein and can induce remission of CML. This large trial found that imat...
Alternative Titles
Full title
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_223933172
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_223933172
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa011573
